Difference between revisions of "Tolcher AW, et al. J. Clin. Oncol. (2012) cited as Ref 584 in DOI: 10.1038/s41392-020-0110-5 (Q9847)"
Jump to navigation
Jump to search
(Created claim: Volume (P103): 30, #quickstatements; #temporary_batch_1590009084631) |
(Created claim: title (P93): Phase I study of RO4929097 a gamma secretase inhibitor of Notch signaling in patients with refractory metastatic or locally advanced solid tumors, #quickstatements; #temporary_batch_1590010982689) |
||
| Property / title | |||
| + | Phase I study of RO4929097 a gamma secretase inhibitor of Notch signaling in patients with refractory metastatic or locally advanced solid tumors (English) | ||
| Property / title: Phase I study of RO4929097 a gamma secretase inhibitor of Notch signaling in patients with refractory metastatic or locally advanced solid tumors (English) / rank | |||
| + | Normal rank | ||
Revision as of 22:04, 20 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Tolcher AW, et al. J. Clin. Oncol. (2012) cited as Ref 584 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Tolcher AW
0 references
2012
0 references
J. Clin. Oncol.
0 references
30
0 references
Phase I study of RO4929097 a gamma secretase inhibitor of Notch signaling in patients with refractory metastatic or locally advanced solid tumors (English)
0 references
